Monoclonal antibodies for treatment of cancer
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-039/395
C07K-016/30
A61K-047/48
출원번호
US-0710828
(2012-12-11)
등록번호
US-8961980
(2015-02-24)
우선권정보
EP-07005258 (2007-03-14)
발명자
/ 주소
Sahin, Ugar
Koslowski, Michael
Tureci, Ozlem
출원인 / 주소
Ganymed Pharmaceuticals AG
대리인 / 주소
McAndrews Held & Malloy, Ltd.
인용정보
피인용 횟수 :
3인용 특허 :
36
초록
The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, and hepatocellular cancer.
대표청구항▼
1. An isolated antibody having the ability of binding to an epitope located within the extracellular domain of the protein comprising the amino acid sequence of SEQ ID NO: 2 and mediating inhibition of proliferation of cells, wherein said cells express a protein comprising the amino acid sequence of
1. An isolated antibody having the ability of binding to an epitope located within the extracellular domain of the protein comprising the amino acid sequence of SEQ ID NO: 2 and mediating inhibition of proliferation of cells, wherein said cells express a protein comprising the amino acid sequence of SEQ ID NO: 2 and/or are characterized by association of a protein comprising the amino acid sequence of SEQ ID NO: 2 with their cell surface. 2. The isolated antibody of claim 1 wherein said inhibition of proliferation of said cells is induced by binding of said antibody to the protein. 3. The isolated antibody of claim 1 wherein said cells are cancer cells. 4. The isolated antibody of claim 3, wherein said cancer cells are selected from the group consisting of tumorigenic breast, lung, gastric, ovarian, liver, colon, pancreatic, esophageal, head-neck, renal, prostate and hepatocellular cancer cells. 5. The isolated antibody of claim 1 which is a monoclonal, chimeric, human or humanized antibody, or an antigen-binding fragment of an antibody. 6. The isolated antibody of claim 1, selected from the group consisting of an IgG1, an IgG2, an IgG3, an IgG4, an IgM, an IgA1, an IgA2, a secretory IgA, an IgD, and an IgE antibody. 7. The isolated antibody of claim 6 selected from the group consisting of an IgG2a and an IgG2b antibody. 8. The isolated antibody of claim 1 wherein the amino acid sequence of said protein consists of the amino acid sequence according to SEQ ID NO: 2. 9. The isolated antibody of claim 1 wherein the antibody binds specifically to a protein comprising the amino acid sequence of SEQ ID NO: 2. 10. The isolated antibody of claim 1 which binds to a conformational epitope of a protein comprising the amino acid sequence of SEQ ID NO: 2 present on the surface of living cells. 11. The isolated antibody of claim 1 wherein said protein comprising the amino acid sequence of SEQ ID NO: 2 is expressed on the surface of said cells. 12. The isolated antibody of claim 1 which is obtainable by a method comprising the step of immunizing an animal with a protein or peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2-10 and 35-79, or an immunogenic fragment or derivative thereof, or a nucleic acid or host cell expressing said protein or peptide, or immunogenic fragment or derivative thereof. 13. An isolated antibody produced by a clone deposited under the accession no. DSM ACC2826 (9B6-2A9), DSM ACC2824 (59D6-2F2), DSM ACC2823 (78H11-1H6), DSM ACC2895 (22-1A-1), DSM ACC2893 (22-2A-1), DSM ACC2896 (22-9B-1), DSM ACC2897 (23-33A-1), DSM ACC2891 (23-19A-1), DSM ACC2892 (4A12 2D4 1A10), or DSM ACC2898 (4E9 1D12 2D4). 14. A hybridoma capable of producing the antibody of claim 1. 15. A hybridoma deposited under the accession no. DSM ACC2826 (9B6-2A9), DSM ACC2824 (59D6-2F2), DSM ACC2823 (78H11-1H6), DSM ACC2895 (22-1A-1), DSM ACC2893 (22-2A-1), DSM ACC2896 (22-9B-1), DSM ACC2897 (23-33A-1), DSM ACC2891 (23-19A-1), DSM ACC2892 (4A12 2D4 1A10), or DSM ACC2898 (4E9 1D12 2D4). 16. A conjugate comprising an antibody of claim 1, coupled to a therapeutic agent. 17. The conjugate of claim 16, wherein the therapeutic agent is a toxin, a radioisotope, a drug or a cytotoxic agent. 18. A conjugate comprising an antibody of claim 13, coupled to a therapeutic agent. 19. The conjugate of claim 18, wherein the therapeutic agent is a toxin, a radioisotope, a drug or a cytotoxic agent. 20. A pharmaceutical composition comprising an antibody of claim 1, and a pharmaceutically acceptable carrier. 21. A pharmaceutical composition comprising an antibody of claim 13, and a pharmaceutically acceptable carrier. 22. A pharmaceutical composition comprising a conjugate of claim 16, and a pharmaceutically acceptable carrier. 23. A pharmaceutical composition comprising a conjugate of claim 18, and a pharmaceutically acceptable carrier.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (36)
Presta Leonard G. ; Snedecor Bradley R., Altered polypeptides with increased half-life.
Ladner Robert C. (Iamsville MD), Computer based system and method for determining and displaying possible chemical structures for converting double- or m.
Winter Gregory Paul (Cambridge GB3) Duncan Alexander Robert (Wimbledon GBX) Burton Dennis Raymond (Sheffield GB3), DNA encoding antibodies with altered effector functions.
Ladner Robert C. (Ijamsville MD) Bird Robert E. (Rockville MD) Hardman Karl (Chevy Chase MD), Immunotheraphy using single chain polypeptide binding molecules.
La Zor Clair G. (13054 Rose St. Cerritos CA 90701), Instrument for locating faults in aircraft passenger reading light and attendant call control system.
Low Philip S. (West Lafayette IN) Horn Mark A. (West Lafayette IN) Heinstein Peter F. (West Lafayette IN), Method for enhancing transmembrane transport of exogenous molecules.
Loughrey Helen C. (Vancouver CAX) Cullis Pieter R. (Vancouver CAX) Bally Marcel B. (Bowen Island CAX) Choi Lewis S. (Burnaby CAX), Method for protein-liposome coupling.
Fanger Michael W. (Lebanon NH) Guyre Paul M. (Hanover NH) Anderson Clark L. (Columbus OH), Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes.
McKinnon ; Jr. Charles N. (Laguna Niguel CA) Peterson Steven F. (West Linn OR) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection device.
Peterson Steven F. (West Linn OR) McKinnon ; Jr. Charles N. (Laguna Niguel CA) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection methods and device.
Venter, J. Craig; Zhang, Jinghui N.; Liu, Xiangjun; Rowe, William; Cravchik, Anibal; Kalush, Francis; Naik, Ashwinikumar; Subramanian, Gangadharan; Woodage, Trevor, Polymorphisms in known genes associated with human disease, methods of detection and uses thereof.
Huston James S. (Newton MA) Charette Marc F. (West Roxbury MA) Cohen Charles M. (Medway MA) Crea Roberto (Boston MA) Keck Peter C. (Millbury MA) Oppermann Hermann (Medway MA) Rueger David C. (West Ro, Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage.
Eppstein Deborah A. (Los Altos CA) Fraser-Smith Elizabeth B. (Los Altos CA) Matthews Thomas R. (Los Gatos CA), Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.